申请人:Kyowa Hakko Kirin Co., Ltd.
公开号:EP2708540A1
公开(公告)日:2014-03-19
Provided are a compound represented by general formula (I), or the pharmaceutically acceptable salt thereof,
(wherein Ra represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom, optionally substituted lower alkyl or cycloalkyl, or R1 and R2 are combined together with the adjacent nitrogen atom thereto to form nitrogen-containing heterocyclic group, and Z represents a bicyclic heterocyclic group in which optionally substituted two six-membered rings are fused to each other, or the like) and the like.
本文提供了通式 (I) 所代表的化合物或其药学上可接受的盐、
(其中 Ra 代表氢原子或类似物,R1 和 R2 可以相同或不同,各自代表氢原子、任选取代的低级烷基或环烷基,或 R1 和 R2 与相邻的氮原子结合在一起形成含氮杂环基团,Z 代表任选取代的两个六元环相互融合的双环杂环基团或类似物)等。